Clinical Trials Logo
  1. Home
  2. Enterobacteriaceae Infections
  3. NCT00573521
  4. Details
NCT00573521 Clinical Trial

Risk Factors for Piperacillin/Tazobactam Resistance in Extended-Spectrum Beta-Lactamase (ESBL) Producing Organisms

Enterobacteriaceae Infections Clinical Trial

Official title:
Risk Factors for Piperacillin/Tazobactam Resistance in Extended-Spectrum Beta-Lactamase (ESBL) Producing Organisms

Clinical Trial Details — Status: Completed

Administrative data
NCT number NCT00573521
Other study ID # PRO07100136
Secondary ID
Status Completed
Phase
First received
Last updated
Start date November 2007
Est. completion date June 2017

Study information
Verified date June 2018
Source University of Pittsburgh
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

This research will be conducted to determine whether risk factors exist for piperacillin/tazobactam resistance in ESBL organisms.

Description:

This is chart review at UPMC. NO human subject interaction will occur.

Recruitment information / eligibility
Status Completed
Enrollment 450
Est. completion date June 2017
Est. primary completion date June 2017
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria:

- Clinical information is collected by chart review of "case" and "control" patients.

- A "case A" patient is defined as follows: One or more clinical cultures are positive for an ESBL producing bacteria and the organism is piperacillin/tazobactam resistant.

- A "case B" patient is defined as follows: One or more clinical cultures are positive for an ESBL producing bacteria and the organism is piperacillin/tazobactam susceptible.

- Additionally, 1 control patient in the hospital at the same time as the case patients will be randomly selected for each case and are not in either case group.

Exclusion Criteria:

- Patients < 18 years of age

Study Design

Related Conditions & MeSH terms

Locations
Country Name City State
United States UPMC Pittsburgh Pennsylvania

Sponsors (1)
Lead Sponsor Collaborator
University of Pittsburgh

Country where clinical trial is conducted

United States, 

Outcome
Type Measure Description Time frame Safety issue
Primary This research will help to identify risk factors for resistance to an antibiotic that is commonly used in the empiric treatment of critically ill patients. 2 years
See also
  Status Clinical Trial Phase
Completed NCT02400268 - Antibiotic Treatment Duration (7 vs 14 Days) Comparison in Blood Stream Infection Causes by Enterobacteriaceae Phase 3
Completed NCT03401242 - Prevalence of ESBL and CPE in French Nursing Homes
Not yet recruiting NCT03967301 - Prevention and Decolonization of Multidrug-resistant Bacteria With Probiotics N/A
Completed NCT02795949 - Study on Reduced Antibiotic Treatment vs Broad Spectrum Betalactam in Patients With Bacteremia by Enterobacteriaceae Phase 3
Completed NCT00573235 - Epidemiology of Community - Associated Extended-spectrum Beta-lactamases (ESBL) Producing Escherichia Coli
Recruiting NCT00404625 - Infections Caused by ESbL-Producing Enterobacteriaceae in Italy N/A
Recruiting NCT03671967 - PipEracillin Tazobactam Versus mERoPENem for Treatment of Bloodstream Infections Caused by Cephalosporin-resistant Enterobacteriaceae (PETERPEN) Phase 4
Enrolling by invitation NCT03924934 - Community-associated Highly-Resistant Enterobacterales
Completed NCT03477084 - Understanding and Modeling Reservoirs, Vehicles and Transmission of ESBL-producing Enterobacteriaceae in the Community and Long Term Care Facilities
Not yet recruiting NCT05632315 - PMT for MDRO Decolonization Phase 2
Withdrawn NCT03527056 - Pilot Study Using Oral Capsule FMT to Decolonize GI CRE Early Phase 1
Completed NCT00826670 - Enterobacteriaceae Producing Extended-spectrum β-lactamases (ESBL) Decolonization Study Phase 4
Not yet recruiting NCT04903886 - Intensive Care Unit Acquired Infections in Patients Colonized With Extended Spectrum Enterobacteriaceae
Completed NCT02482051 - Ultra Rapid Culture Independent Detection of High-Priority Carbapenem Resistant Enterobacteriaceae Directly From Blood
Recruiting NCT00894036 - The Burden and Genetic Variability of Extended-Spectrum ß-Lactamase (ESBL) - Producing Pathogens in Swiss Children N/A
Suspended NCT05355350 - PipEracillin/Tazobactam Versus mERoPENem for Treatment of AmpC Producing Blood Stream Infections Phase 4
Recruiting NCT05516433 - Effect of Imipenem and Meropenem on the Digestive Microbiota and the Emergence and Carriage of Multidrug-resistant Bacteria
Recruiting NCT02450942 - 18F-FDS PET/CT in Healthy Volunteers and Patients With Suspected Infection Early Phase 1
Recruiting NCT05035342 - Fecal Transplantation to Eradicate Colonizing Emergent Superbugs Phase 3
Not yet recruiting NCT03411590 - The Effect of Fortified Growing-up Milk on Growth and Micronutrient Status of Nigerian Toddlers N/A